Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Synopsis

Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995–2014

Mohammadreza Shaghaghi1, Shohreh Shahmahmoodi1, Hassan Abolhassani, Saeed Soleyman-jahi, Leila Parvaneh, Sussan Mahmoudi, Zahra Chavoshzadeh, Reza Yazdani, Seyed Mohsen Zahraei, Mohsen Ebrahimi, Mohammad H. Eslamian, Hamideh Tabatabaie, Maryam Yousefi, Yaghoob M. Kandelousi, Aliasghar Oujaghlou, Nima Rezaei, and Asghar AghamohammadiComments to Author 
Author affiliations: Tehran University of Medical Sciences, Tehran, Iran (M. Shaghaghi, S. Shahmahmoodi, H. Abolhassani, S. Soleyman-jahi, L. Parvaneh, M. Ebrahimi, M.H. Eslamian, N. Rezaei, A. Aghamohammadi); Universal Scientific Education and Research Network, Tehran (M. Shaghaghi, H. Abolhassani, S. Soleyman-jahi, R. Yazdani, N. Rezaei, A. Aghamohammadi); Research Center for Immunodeficiences, Tehran (M. Shaghaghi, H. Abolhassani, N. Rezaei, A. Aghamohammadi); Tehran University of Medical Sciences School of Public Health, Tehran (S. Shahmahmoodi, H. Tabatabaie, M. Yousefi, Y.M. Kandelousi, A. Oujaghlou); Ministry of Health and Medical Education, Tehran (S. Mahmoudi, S.M. Zahraei); Shaheed Beheshti Medical University, Tehran (Z. Chavoshzadeh); Isfahan University of Medical Sciences School of Medicine, Isfahan, Iran (R. Yazdani); Children’s Medical Center, Tehran (M. Ebrahimi, M.H. Eslamian)

Main Article

Table 3

Immunologic findings for 14 patients infected with iVDPV, Iran, 1995–2014*

Patient no. Underlying immunodeficiency Cells/μL†
 Concentration, mg/dL‡
Leukocytes ALC CD3 CD4 CD8 CD19 IgG IgM IgA
1 Undefined hypogammaglobulinemia NA NA NA NA NA NA NA NA NA
2 MHC2 6,300 3,642 1,216 608 607 1,460 200 <10 <10
3 SCID 1,700 731 138 96 32 10 45 <10 <10
4 XLA 6,500 3,375 2,700 1,404 1,290 35 556 <10 <10
5 SCID 6,800 2,589 336 184 185 160 <10 <10 <10
6 XLA 8,500 4,000 2,760 1,920 835 40 20 58 25
7 NBS 6,050 1,040 527 206 264 10 30 22 <10
8 XLA 9,400 4,470 4,201 2,547 1,564 10 80 <10 <10
9 SCID 7,500 3,825 1,092 841 279 2,371 <10 45 <10
10 SCID 7,200 2,174 652 543 163 1,413 40 <10 <10
11 Mu heavy chain 14,400 10,080 8,769 4,636 4,132 110 600§ <10 <10
12 NA¶ NA NA NA NA NA NA NA NA NA
13 XLA 10,300 4,738 4,264 3,506 663 30 292 <10 <10
14 Agammaglobulinemia# 10,600 6,254 5,628 4,377 1,375 81 297 34 14

*ALC, absolute lymphocyte count; iVDPV, immunodeficiency-associated vaccine-derived poliovirus; MHC2, major histocompatibility class 2 deficiency; NA, not available; NBS, Nijmegen breakage syndrome; SCID, severe combined immunodeficiency; XLA, X-linked agammaglobulinemia.
†Reference range for total leukocytes, 5,000–10,000 cells/μL; reference range for ALC, 3,000–10,800 cells/μL; reference ranges for lymphocyte subpopulations: CD3, 1,900–5,900 cells/μL; CD4, 1,400–4,300 cells/μL; CD8, 500–1,700 cells/μL; CD19, 610–2,600 cells/μL.
‡Reference ranges for serum immunoglobulins: IgG, 246–904 mg/dL; IgM, 40–143 mg/dL; IgA, 27–66 mg/dL.
§Patient received intravenous immunoglobulin at a primary medical center before blood sampling was initiated.
¶Not determined because patient died.
#Patient was candidate for gene analysis for definitive diagnosis.

Main Article

1These authors contributed equally to this article.

Page created: September 19, 2016
Page updated: September 19, 2016
Page reviewed: September 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external